Hellman & Friedman-backed Cordis completed the acquisition of MedAlliance for $1.14bn.

Hellman & Friedman-backed Cordis, a firm engaged in the development and manufacturing of interventional cardiovascular and endovascular technologies, completed the acquisition of MedAlliance, a Swiss-based medical technology company, for $1.14bn. "The Cordis acquisition will accelerate access to this breakthrough technology for patients around the globe suffering from coronary and peripheral disease. I want to thank our entire MedAlliance team - including physicians, distributors and clinical patients - who have succeeded in disrupting the coronary and peripheral markets to provide a safe and effective new technology. The arsenal of SELUTION SLR DEB clinical data is designed to change medical practice and improve patient outcomes," Jeffrey B. Jump, MedAlliance Founder, Chairman and CEO.